" /> Dose-dense AC Followed by Paclitaxel/Pertuzumab/Trastuzumab Regimen - CISMeF





Preferred Label : Dose-dense AC Followed by Paclitaxel/Pertuzumab/Trastuzumab Regimen;

NCIt synonyms : Dose-dense AC Followed by Paclitaxel-Pertuzumab-Trastuzumab; Dose-dense AC Followed by Paclitaxel/Pertuzumab/Trastuzumab; Dose-dense AC Followed by Paclitaxel-Pertuzumab-Trastuzumab Regimen; Dose-dense Doxorubicin/Cyclophosphamide Followed by Paclitaxel/Pertuzumab/Trastuzumab Regimen; Dose-dense Adriamycin/Cytoxan Followed by Taxol/Herceptin/Perjeta; Dose-Dense AC-THP; Dose-dense AC Followed by Paclitaxel/Trastuzumab/Pertuzumab Regimen;

NCIt related terms : ddAC-THP (Paclitaxel) (trastuzumab-anns); ddAC-THP (Paclitaxel) (trastuzumab-dttb); ddAC-THP (Paclitaxel); ddAC-THP (Paclitaxel) (trastuzumab-pkrb); ddAC-THP (Paclitaxel) (trastuzumab-herw); ddAC-THP (Paclitaxel) (trastuzumab-qyyp); ddAC-THP (Paclitaxel) (trastuzumab-zerc); ddAC-THP (Paclitaxel) (trastuzumab-dkst);

NCIt definition : A regimen consisting of dose-dense cyclophosphamide and doxorubicin followed by paclitaxel, pertuzumab and trastuzumab that can be used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.;

NCI Metathesaurus CUI : CL1664633;

Codes from synonyms : 128918; 129403; 129306; 129209; 128821; 129112; 129015; 63533;

Details


You can consult :


Nous contacter.
07/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.